Cardiorenal Syndrome and Contemporary Therapeutic Paradigms in Chronic Kidney Disease: A Comprehensive Narrative Review

Abstract

Chronic kidney disease (CKD) and cardiovascular disease (CVD) are bidirectionally linked, with declining renal function amplifying cardiovascular injury and preexisting CVD accelerating renal decline. As the estimated glomerular filtration rate falls, cardiovascular mortality escalates sharply, accounting for up to 50% of deaths in advanced CKD. The objective of this review is to evaluate the prevalence and mechanisms of cardiovascular complications - specifically ischemic heart disease, heart failure, and vascular calcification - in CKD patients and to synthesize clinical trial evidence regarding modern therapeutic interventions. A comprehensive narrative review was conducted by searching across academic databases, including PubMed (MEDLINE), Europe PMC, OpenAlex and Google Scholar, for highly peer-reviewed literature published between 2015 and 2026. A qualitative selection process yielded 28 high-quality studies focusing on the pathophysiology and contemporary therapeutic management of cardiorenal syndrome (CRS) in CKD. The extensive burden of structural and ischemic complications cannot be attributed solely to traditional risk factors. CRS is driven by a complex interplay of non-traditional mechanisms, including chronic inflammation, uremic toxin accumulation, persistent renin-angiotensin-aldosterone system activation, and profound mineral-bone disorders. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are now foundational disease-modifying therapies for proteinuric CKD, while glucagon-like peptide-1 (GLP-1) receptor agonists offer significant atherosclerotic and metabolic benefits. CKD is a profound cardiovascular risk state. Mitigating the severe outcomes of CRS requires early diagnostic screening, albuminuria-based risk stratification, and integrated care to rapidly deploy targeted therapies that simultaneously prevent progressive kidney failure and fatal CVD events.